Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Response Biomedical (V.RBM) -- Ignore unavailable to you. Want to Upgrade?

To: Dick Martin who wrote (354)	11/23/2000 12:12:48 PM
From: Rob	Read Replies (1) \| Respond to of 655

Not really. Biosite is the "competition" I've held up as a positive comparison for Response the last two years. Their BNP test is on the same platform as their cardiac test which is getting a worse reputation every day that its in the market. I've heard of in-house tests done by a company which showed 20% of healthy people tested with the Biosite test to be having heart attacks - needless to say there was a lot of laughing and it spawned a lot of jokes (of course I am saying this as heresay and not fact:)). Recall my earlier posts on the numerous advantages RAMP has over Biosite Triage. Also recall my post on Ischemia (post #325 which read as follows: "Note that this announcement is even more significant than it appears. The top two experts in the world on point-of-care diagnostics are on the Ischemia scientific advisory board - Christenson and Wu. z9.zland.com. Wu is also on Biosite's advisory board...and they chose Response over Biosite (now C$1.4 billion dollar market cap)." To provide further validation of the importance of the Response-Iscemia deal (whereby Iscemia has already developed and patented an ischemia marker), Biosite announced about a week later that they were BEGINNING a program to DEVELOP an ischemia marker. Biosite has no major marketing partners ....for good reason....it comes back to my point that a marketing deal between Response and a major company means many things and will be the major catalyst to move the stock. IMO Biosite has proven there is a market demand and by having an inferior product has opened the door for a much better 2nd generation product, as so often is the case, to be the big success. Regards, Rob